{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:54:00Z","timestamp":1790013240109,"version":"4.0.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1121940"],"award-info":[{"award-number":["APP1121940"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015988","name":"Norman Beischer Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015988","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001782","name":"University of Melbourne","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001782","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.eclinm.2026.103779","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T09:33:33Z","timestamp":1770111213000},"page":"103779","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Safety and pharmacokinetics of sulfasalazine and its metabolite sulfapyridine for treatment of preterm preeclampsia in Australia (SIP): an early phase, unblinded, single-arm, proof of concept clinical trial"],"prefix":"10.1016","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7267-3293","authenticated-orcid":false,"given":"Elif","family":"Kadife","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Decloedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6074-2362","authenticated-orcid":false,"given":"Vanessa","family":"Louw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohra Bibi","family":"Abdulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1542-4976","authenticated-orcid":false,"given":"Tracy","family":"Kellermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5365-0320","authenticated-orcid":false,"given":"Veshni","family":"Pillay-Fuentes Lorente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0406-8964","authenticated-orcid":false,"given":"Catherine","family":"Cluver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6596-5872","authenticated-orcid":false,"given":"Anna","family":"Middleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tu'uhevaha J.","family":"Kaitu'u-Lino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6263-0030","authenticated-orcid":false,"given":"Joanne M.","family":"Said","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1439-7016","authenticated-orcid":false,"given":"Fiona C.","family":"Brownfoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2026.103779_bib1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41572-023-00417-6","article-title":"Pre-eclampsia","volume":"9","author":"Dimitriadis","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.eclinm.2026.103779_bib2","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/uog.26032","article-title":"Clinical utility of sFlt-1 and PlGF in screening, prediction, diagnosis and monitoring of pre-eclampsia and fetal growth restriction","volume":"61","author":"Stepan","year":"2023","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.eclinm.2026.103779_bib3","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/2632637","article-title":"Clinical presentation of preeclampsia and the diagnostic value of proteins and their methylation products as biomarkers in pregnant women with preeclampsia and their newborns","volume":"2018","author":"Portelli","year":"2018","journal-title":"J Pregnancy"},{"key":"10.1016\/j.eclinm.2026.103779_bib4","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ebiom.2019.02.013","article-title":"Sulfasalazine reduces placental secretion of antiangiogenic factors, up-regulates the secretion of placental growth factor and rescues endothelial dysfunction","volume":"41","author":"Brownfoot","year":"2019","journal-title":"eBioMedicine"},{"key":"10.1016\/j.eclinm.2026.103779_bib5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/0016-5085(81)90193-1","article-title":"Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome","volume":"80","author":"Mogadam","year":"1981","journal-title":"Gastroenterology"},{"key":"10.1016\/j.eclinm.2026.103779_bib6","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.placenta.2023.01.001","article-title":"Sulfasalazine for the treatment of preeclampsia in a nitric oxide synthase antagonist mouse model","volume":"132","author":"Binder","year":"2023","journal-title":"Placenta"},{"key":"10.1016\/j.eclinm.2026.103779_bib7","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1046\/j.1365-2036.2001.00962.x","article-title":"Population-based case control study of the safety of sulfasalazine use during pregnancy","volume":"15","author":"N\u00f8rg\u00e5rd","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.eclinm.2026.103779_bib8","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.reprotox.2007.11.010","article-title":"Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis","volume":"25","author":"Rahimi","year":"2008","journal-title":"Reprod Toxicol"},{"key":"10.1016\/j.eclinm.2026.103779_bib9","doi-asserted-by":"crossref","first-page":"406","DOI":"10.2165\/00003088-197601060-00002","article-title":"Clinical pharmacokinetics of sulphasalazine","volume":"1","author":"Das","year":"1976","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.eclinm.2026.103779_bib10","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00003088-198510040-00001","article-title":"Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid","volume":"10","author":"Klotz","year":"1985","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.eclinm.2026.103779_bib11","doi-asserted-by":"crossref","first-page":"582","DOI":"10.5694\/mja2.52312","article-title":"A summary of the 2023 society of obstetric medicine of Australia and New Zealand (SOMANZ)","volume":"220","author":"Shanmugalingam","year":"2024","journal-title":"Med J Aust"},{"key":"10.1016\/j.eclinm.2026.103779_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115633","article-title":"An LC-MS\/MS method for the simultaneous quantitation of sulfasalazine and sulfapyridine in human placenta","volume":"235","author":"Louw","year":"2023","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.eclinm.2026.103779_bib13","doi-asserted-by":"crossref","first-page":"291","DOI":"10.5694\/mja11.11331","article-title":"Australian national birthweight percentiles by sex and gestational age, 1998-2007","volume":"197","author":"Dobbins","year":"2012","journal-title":"Med J Aust"},{"key":"10.1016\/j.eclinm.2026.103779_bib14","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s10620-008-0481-x","article-title":"A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis","volume":"54","author":"Nikfar","year":"2009","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.eclinm.2026.103779_bib15","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jchromb.2010.12.034","article-title":"Determination of sulphasalazine and its main metabolite sulphapyridine and 5-aminosalicylic acid in human plasma by liquid chromatography\/tandem mass spectrometry and its application to a pharmacokinetic study","volume":"879","author":"Gu","year":"2011","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.eclinm.2026.103779_bib16","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3109\/00365528109182032","article-title":"Placental transfer of sulphasalazine and sulphapyridine and some of its metabolites","volume":"16","author":"J\u00e4rnerot","year":"1981","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.eclinm.2026.103779_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.00168","article-title":"Pharmacogenomics of hypertension and preeclampsia: focus on gene\u2013gene interactions","volume":"9","author":"Luizon","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.eclinm.2026.103779_bib18","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1517\/17425255.3.4.557","article-title":"Alterations in drug disposition during pregnancy","volume":"3","author":"Hodge","year":"2007","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.eclinm.2026.103779_bib19","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1002\/jcph.2227","article-title":"Physiologic changes during pregnancy and impact on small-molecule drugs, biologic (monoclonal antibody) disposition, and response","volume":"63","author":"Eke","year":"2023","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.eclinm.2026.103779_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5414\/CPP48001","article-title":"Phenotyping with sulfasalazine - time dependence and relation to NAT2 pharmacogenetics","volume":"48","author":"Kuhn","year":"2010","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.eclinm.2026.103779_bib21","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1038\/s41467-025-58533-8","article-title":"Maternal gut microbiota influences immune activation at the maternal-fetal interface affecting pregnancy outcome","volume":"16","author":"Giugliano","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.eclinm.2026.103779_bib22","article-title":"Longitudinal change of gut microbiota in hypertensive disorders in pregnancy: a nested case\u2013control and Mendelian randomization study","volume":"13","author":"Wu","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.eclinm.2026.103779_bib23","series-title":"StatPearls [Internet]","article-title":"Sulfasalazine. 2024 Mar 21","author":"Choi","year":"2025"},{"key":"10.1016\/j.eclinm.2026.103779_bib24","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1136\/bmj.2.6204.1553","article-title":"Placental and mammary transfer of sulphasalazine","volume":"2","author":"Khan","year":"1979","journal-title":"Br Med J"},{"key":"10.1016\/j.eclinm.2026.103779_bib26","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.3389\/fphys.2018.01502","article-title":"Drug transport at the brain and endothelial dysfunction in preeclampsia: implications and perspectives","volume":"9","author":"Torres-Vergara","year":"2018","journal-title":"Front Physiol"},{"key":"10.1016\/j.eclinm.2026.103779_bib27","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1046\/j.1365-2036.1998.00420.x","article-title":"Review article: the management of inflammatory bowel disease during pregnancy","volume":"12","author":"Subhani","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.eclinm.2026.103779_bib28","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/1753495X20919214","article-title":"Pregnancy and medications in inflammatory bowel disease","volume":"14","author":"Cao","year":"2021","journal-title":"Obstet Med"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258953702600026X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258953702600026X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T20:30:54Z","timestamp":1784579454000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258953702600026X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":27,"alternative-id":["S258953702600026X"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.103779","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and pharmacokinetics of sulfasalazine and its metabolite sulfapyridine for treatment of preterm preeclampsia in Australia (SIP): an early phase, unblinded, single-arm, proof of concept clinical trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.103779","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103779"}}